Table 1.
Approved ‘direct-acting antivirals’ for the treatment of chronic hepatitis C (5/2015) (modified according to [44])
| Medication | HCV genotype | Dosing |
|---|---|---|
| HCV NS3/4A protease inhibitors | oral | |
| Boceprevir (VICTRELIS®) | 1 | not recommended anymore |
| Telaprevir (INCIVEK®, INCIVO®) | 1 | not recommended anymore |
| Simeprevir (OLYSIO® (US), SOVRIAD® (Japan), GALEXOS® (Canada)) | 1 & 4 | 150 mg (1 × 150 mg capsules) once daily; 100 mg in Japan |
| Paritaprevir (co-formulated with ritonavir and ombitasvir as VIEKIRAX®) | 1 & 4 | 150 mg once daily (2 × 75 mg, 2 tablets once daily; only in combination with dasabuvir or ribavirin) |
| Asunaprevir (SUNVEPRA®) | 1 & 4 | 100 mg (1 × 100 mg capsules) twice daily (only available in Japan in combination with daclatasvir) |
| HCV NS5B polymerase inhibitors | oral | |
| Sofosbuvir (SOVALDI®) (nucleotide analogue) | 1–6 | 400 mg (1 × 400 mg tablets) once daily |
| Dasabuvir (EXVIERA®) (non-nucleoside analogue) | 1 | 250 mg (1 × 250 mg tablets) twice daily (only in combination with VIEKIRAX®) |
| HCV NS5A replication complex inhibitor | oral | |
| Daclatasvir (DAKLINZA®) | 1–6 | 60 mg (1 × 60 mg tablets) once daily |
| Ledipasvir (co-formulated with sofosbuvir as HARVONI®) | 1, 3 & 4 | 90 mg (1 × 90 mg tablets) once daily |
| Ombitasvir (co-formulated with paritaprevir/ ritonavir as VIEKIRAX®) | 1 & 4 | 25 mg once daily (2 × 12.5 mg, 2 tablets once daily) |